- AU$149.74m
- AU$106.76m
- AU$16.23m
Brief: Orthocell Receives Regulatory Approval To Commence Sales Of Striate In Canada
Australia's Orthocell set for biggest gain in 7 months on Canada approval
Brief: Orthocell Ltd Says Record Revenue Of A$1.84M Has Been Achieved For June 24 Quarter
Australia's Orthocell gains on strong June quarter results
Brief: Orthocell Applies For Australian Market Approval For Smrtgraft Tendon Repair Device
Brief: Orthocell Says HY Loss Attributable A$5.2 Million Versus Loss A$4.1 Million
Brief: Orthocell Says Strategic Placement To Raise A$3.5 Million
Brief: Orthocell Ltd Seeks Trading Halt
Brief: Orthocell Says Application To Market & Sell Remplir In Singapore, Accepted For Review By Health Services Authority Of Singapore
Brief: Orthocell Posts HY Revenue Of A$3.2 Million
Brief: Orthocell Says Stewart Washer Retires From Orthocell Board
Brief: Orthocell Currently Conducting Clinical Trial Focussed On Treatment Of Tennis Elbow
Australia's Orthocell jumps most in 7 weeks as quarterly revenue grows
Brief: Orthocell Says Striate+™ Re-Certified Under New European Medical Device Regulations
Brief: Orthocell Appoints John Van Der Wielen As Independent Non-Executive Chairman
Australia's Orthocell rises on new appointments to advisory board
Brief: Orthocell Says Loss For Half-Year Attributable A$4.1 Mln
Brief: Orthocell Says Remplir™ Granted Inclusion On Australian Prostheses List
Orthocell hits highest in over 2 weeks after new distribution deal